Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study

Claire S Waddington, W T Walker, C Oeser, A Reiner, T John, S Wilkins, M Casey, P E Eccleston, R J Allen, I Okike, S Ladhani, E Sheasby, K Hoschler, N Andrews, P Waight, A C Collinson, P T Heath, A Finn, S N Faust, M D SnapeE Miller, Andrew Pollard

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.
Original languageEnglish
Article numberc2649
JournalBMJ
Volume340
DOIs
Publication statusPublished - 27 May 2010

Fingerprint Dive into the research topics of 'Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study'. Together they form a unique fingerprint.

Cite this